AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03694496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-led theory-based intervention group
Description: We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader.
Study NCT04601948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Activity Intervention
Description: Eligible participants will receive a Fitbit activity monitor and access to our mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
Study NCT00436345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
Study NCT01614314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preceptorship
Description: After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
Study NCT01614314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auto-instructional guide
Description: After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
Study NCT00922948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
Study NCT00922948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
Study NCT03378713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP 1: Long testosterone
Description: Application of testosterone in transdermal gel during the 2 cycles prior to initiation of controlled ovarian stimulation and until the onset of second menstruation (approximately 56 days). The COS begins the day after the last testosterone application
Study NCT03378713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP 2: Short testosterone
Description: Application of testosterone in transdermal gel begins on day 21 of menstrual cycle, from the luteal phase of the cycle prior to initiation of controlled ovarian stimulation and until menstruation (approximately 10 days). The COS begins the day after the last testosterone application.
Study NCT03378713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP 3: Control
Description: The COS starts directly on the second day of the cycle without prior medication.
Study NCT02140814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacinamide
Study NCT04094571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) Control Protocol
Description: To measure the delay, the motor will take the tricycle crank to pre-specified angles and then hold that position while various combinations of the quadriceps femoris and the gluteal muscle groups are stimulated in study participants.
Study NCT04094571 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) Angle Protocol
Description: To determine the effect of the crank angle on the FES delay and the muscle control effectiveness, the crank is positioned at a pre-specified angle, with various muscle groups being stimulated while holding this position. The motor then takes the crank to another angle and the process is repeated.
Study NCT04066972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training in a room cooled to 16°C
Description: A total of 30 training sessions will be conducted in 10 weeks for 30 minutes per session and 3 times per week in a cool room (16⁰ C) on a treadmill that is equipped with safety straps to prevent falls. A pneumatic harness system will be used to provide 10% body-weight support during training sessions. The participants will start exercising on the treadmill at 80% of their self-selected walking speed with 1% incline and will increase as per their tolerance (will progress weekly based on 40-65% heart rate reserve). Heart rate, perceived fatigue and rating of perceived exertion will be monitored continuously during exercise sessions. Initial training will commence with intermittent rest periods \[1 to 5 minutes\] as requested by the participants and will be progressed to a maximum of 30-minute continuous treadmill walking.
Study NCT03284736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resorbable membrane
Study NCT03284736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periapical surgery without membrane
Description: after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
Study NCT02385422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
Study NCT01381432 — intervention group
Intervention type: DRUG
Intervention: Azathioprine
Description: At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
Study NCT01779973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Observed Dosing
Study NCT03600662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TriRec
Description: Trileaflet Reconstruction of the Aortic Valve
Study NCT03600662 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Description: Biological Prosthesis, Device: St. Jude Medical Trifecta GT
Study NCT02385422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
Study NCT01756131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1265744 injectable suspension
Description: 200 milligram per milliliter sterile solution for injection
Study NCT01756131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo to match injectable suspension
Description: placebo
Study NCT03698435 — intervention group
Intervention type: DRUG
Intervention: Ganciclovir
Description: Intravenous ganciclovir + TDM
Study NCT03698435 — intervention group
Intervention type: DRUG
Intervention: Valganciclovir
Description: Oral valganciclovir + TDM
Study NCT02459795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingenol Mebutate (Perrigo)
Study NCT02459795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol Mebutate (Reference)
Study NCT02459795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Study NCT01285115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Study NCT01285115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KyungBangn-Gamisoyosan-x-gwarip
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Study NCT01285115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KyungBangn Gamisoyosan
Description: AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
Study NCT03794336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT01389752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: Administered orally
Study NCT03794336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT03794336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT01389752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Administered orally
Study NCT03794336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT01709435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01709435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03794336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT03794336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Pharmaceutical form: tablet~Route of administration: oral administration
Study NCT00373113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250 mg/m\^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
Study NCT00373113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib malate
Description: 37.5 mg daily, continuous dosing
Study NCT01709435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03720431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TTAC-0001 and pembrolizumab combination
Description: * Investigational product (IP): TTAC-0001 and Pembrolizumab (Merck, Keytruda®)~* Treatment groups: 3 dose levels~  * Dose level 1 (optimal starting dose): TTAC-0001 12 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 2 (first escalation dose): TTAC-0001 16 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~ * Dose level 0 (de-escalation dose): TTAC-0001 8 mg/kg on D1, D8 and D15 + Pembrolizumab 200 mg on D1~* Cycle: 3 weeks (21 days per cycle)
Study NCT01250600 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: Daily home exercise for 3 months
Study NCT01250600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Daily home exercise for 3 months
Study NCT00825500 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled Placebo
Description: Inhaled Staccato placebo (0 mg)
Study NCT05466617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health for Physical Activity Behavior Change
Description: All participants received visualized step-by-step instructions (eg, search and download on Google Play or App Store, user registration, goal setting, and PA behavior tracking) on the assigned PA app (PuzzleWalk or Google Fit) and used it from the beginning of the intervention start (fourth week) until the end of the intervention (eighth week). Both the PuzzleWalk and Google Fit groups received reminders regarding the use of the PA app during the first week of the intervention period and autonomously continued to use the app until the intervention ended.
Study NCT00825500 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Loxapine 1.25 mg
Description: Inhaled Staccato Loxapine 1.25 mg, single dose
Study NCT00825500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Loxapine 2.5 mg
Description: Inhaled Staccato Loxapine 1.25 mg, single dose
Study NCT04457804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual ACT Workshop for Emotional Eating
Description: This is a brief online intervention using Acceptance and Commitment Therapy (ACT) technique to target and reduce emotional eating. The intervention will be modeled after Frayn and Knäuper's 1-day ACT workshop for emotional eating intervention, which was derived from Forman and colleagues' Mind Your Health Program. During the workshop, the following topics will be discussed, based on the three processes of ACT: (1) values clarification/commitment, (2) acceptance/distress tolerance, and (3) mindfulness/awareness.
Study NCT01485757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
Study NCT03285737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: Supplement provided twice daily in 30g doses
Study NCT03285737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Collagen
Description: Supplement provided twice daily in 30g doses
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum total 25 hydroxycholecalciferol 25(OH) vitamin D
Description: Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: complete blood count (CBC)
Description: for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum calcium level
Description: measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: erythrocyte sedimentation rate (ESR)
Description: it is an indicator of activity in inflammatory bowel disease
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: C-reactive protein (CRP)
Description: it is an indicator for increased possibility of infections
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum creatinine
Description: for assessment of renal function
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum albumin level
Description: for possibility of malabsorbtion in patients with inflammatory bowel disease
Study NCT03841630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3437943
Description: Administered subcutaneously (SC)
Study NCT03841630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: seum alanine aminotransferase
Description: for assessment of liver function
Study NCT03278353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.~The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log.
Study NCT03278353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum potassium level
Description: indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease
Study NCT02807584 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELECT
Study NCT03496246 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum phosphurus level
Description: measurement of phosphurus level as it is closely related to vitamin d with its effects on its level
Study NCT01338454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transamin
Description: TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
Study NCT01652469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
Study NCT01652469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 as an IV infusion every 21 days.
Study NCT00337675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
Study NCT00337675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
Study NCT00337675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV over 30 minutes; Days 1 and 15
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV over 30 minutes; Days 1 and 15
Study NCT01830504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.~A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment.
Study NCT02742285 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Artemether + lumefantrine
Description: A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
Study NCT01056627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: PO twice daily (BID); Days 1-7, 15-21
Study NCT01056627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
Study NCT04319978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Dexamethasone is a synthetic corticosteroid. Dexamethasone is an adequate measure for reducing pain and edema in the post-operative recuperation period following 3rd molar surgery. A single dose of IM 8mg dexamethasone will be used for each patient.
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV over 60 minutes; Days 1 and 15
Study NCT03535727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: IV over 30 minutes; Days 1 and 15
Study NCT02429414 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Video Double Lumen Tube (DLT)
Description: Participant receives non-video double lumen tube (DLT) placement before surgery.
Study NCT02429414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiberoptic Bronchoscopy (FOB)
Description: Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.